Skip to main content

Table 4 Course of liver enzyme levels in patients initially treated with zinc, grouped by treatment response

From: Zinc monotherapy is effective in Wilson’s disease patients with mild liver disease diagnosed in childhood: a retrospective study

    Median UI/L (range) P value
ALT (UI/L) Baseline Responder 201 (12–502) .30
Non-responder 57 (50–64)
6 months Responder 72 (24–233) .93
Non-responder 82 (64–101)
12 months Responder 51 (26–94) ≤.001
Non-responder 172 (132–212)
24 months Responder 41 (23-80) -
Non-responder -
>36 months Responder 49 (18-79)  
Non-responder -  
AST (UI/L) Baseline Responder 67 (22–168) .42
Non-responder 59 (49–69)
6 months Responder 46 (34–83) .81
Non-responder 56 (48–64)
12 months Responder 44 (35–66) ≤.001
Non-responder 156 (92–221)
24 months Responder 40 (26-74) -
Non-responder -
>36 months Responder 36 (19-61) -
Non-responder -
GGT (UI/L) Baseline Responder 36 (13–119) .34
Non-responder 18 (16–21)
6 months Responder 30 (13–49) .35
Non-responder 40 (22–59)
12 months Responder 22 (11–55) ≤.001
Non-responder 86 (45–127)
24 months Responder 18 (13-38) -
Non-responder -
>36 months Responder 16 (13-43) -
Non-responder -